Author:
Puliafito Ivana,Esposito Francesca,Prestifilippo Angela,Marchisotta Stefania,Sciacca Dorotea,Vitale Maria Paola,Giuffrida Dario
Abstract
Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell variants, medullary TC (MTC), anaplastic TC (ATC), and poorly differentiated TC (PDTC). The standard of care in DTC consists of surgery together with radioactive iodine (131I) therapy and thyroid hormone, but patients with MTC do not benefit from 131I therapy. Patients with advanced TC resistant to 131I treatment (RAI-R) have no chance of cure, as well as patients affected by ATC and progressive MTC, in which conventional therapy plays only a palliative role, representing, until a few years ago, an urgent unmet need. In the last decade, a better understanding of molecular pathways involved in the tumorigenesis of specific histopathological subtypes of TC has led to develop tyrosine kinase inhibitors (TKIs). TKIs represent a valid treatment in progressive advanced disease and were tested in all subtypes of TC, highlighting the need to improve progression-free survival. However, treatments using these novel therapeutics are often accompanied by side effects that required optimal management to minimize their toxicities and thereby enable patients who show benefit to continue treatment and obtain maximal clinical efficacy. The goal of this overview is to provide an update on the current use of the main drugs recently studied for advanced TC and the management of the adverse events.
Subject
Endocrinology, Diabetes and Metabolism
Reference136 articles.
1. International Agency for Research on CancerThyroid. Global Cancer Observatory
2. Surveillance Epidemiology and End Results Program: Seer Stat Facts: Thyroid Cancer
3. WHO Classification of Tumours of Endocrine Organs;Lloyd,2017
4. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma;Wells;Thyroid,2015
5. Poorly Differentiated Carcinoma of the Thyroid. A Clinicopathologic Entity for a High-Risk Group of Papillary and Follicular Carcinomas;Sakamoto;Cancer,1983
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献